David Krempa - Oct 2, 2024 Form 4 Insider Report for Eton Pharmaceuticals, Inc. (ETON)

Role
Chief Business Officer
Signature
/s/ David Krempa
Stock symbol
ETON
Transactions as of
Oct 2, 2024
Transactions value $
$0
Form type
4
Date filed
10/4/2024, 04:19 PM
Previous filing
Feb 15, 2024
Next filing
Jan 6, 2025
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction ETON Restricted Stock Units Award $0 +42.1K +5.14% $0.00 861K Oct 2, 2024 Common Stock 42.1K Direct F1, F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Each restricted stock unit represents a contingent right to receive one share of ETON Common Stock.
F2 The restricted stock units vest in four equal annual installments beginning October 2, 2025, contingent upon the reporting person being employed by the issuer on the date(s) of vesting.

Remarks:

The reporting person has authorized and designated the named person to file this Form 4 on the reporting person's behalf for indefinite duration.